Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Notes Payables (2017 - 2025)

Historic Notes Payables for vTv Therapeutics (VTVT) over the last 10 years, with Q3 2025 value amounting to $328000.0.

  • vTv Therapeutics' Notes Payables changed N/A to $328000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $328000.0, marking a year-over-year change of. This contributed to the annual value of $191000.0 for FY2023, which is 1473.21% down from last year.
  • vTv Therapeutics' Notes Payables amounted to $328000.0 in Q3 2025.
  • vTv Therapeutics' 5-year Notes Payables high stood at $636000.0 for Q3 2021, and its period low was $191000.0 during Q4 2023.
  • In the last 4 years, vTv Therapeutics' Notes Payables had a median value of $328000.0 in 2025 and averaged $380714.3.
  • The largest annual percentage gain for vTv Therapeutics' Notes Payables in the last 5 years was 20476.19% (2021), contrasted with its biggest fall of 7315.32% (2021).
  • vTv Therapeutics' Notes Payables (Quarter) stood at $256000.0 in 2021, then fell by 12.5% to $224000.0 in 2022, then dropped by 14.73% to $191000.0 in 2023, then surged by 71.73% to $328000.0 in 2025.
  • Its Notes Payables was $328000.0 in Q3 2025, compared to $191000.0 in Q4 2023 and $473000.0 in Q3 2023.